NAD+ Injection

Nicotinamide adenine dinucleotide (NAD+) is an essential cellular coenzyme that facilitates energy metabolism and cellular repair. (Source). At Opt Health, we evaluate a blood panel of 55+ biomarkers covering hormones, inflammation, and cardiovascular risk before recommending any therapeutic compound. Your physician reviews your health history, baseline blood tests, and current medications during a 1:1 consultation. (Source).

Nicotinamide Adenine Dinucleotide Biology and Cellular Energy Function

Nicotinamide adenine dinucleotide functions in every living cell as a required coenzyme for metabolic energy transfer and cellular maintenance. The molecule cycles between an oxidized state designated as NAD+ and a reduced state designated as NADH. This biochemical redox cycling allows cells to transfer electrons during metabolic processes that produce cellular energy. (Source).

Beyond its role in cellular respiration, the coenzyme serves as a cofactor for enzymes involved in DNA repair, cellular stress responses, and metabolic regulation. Research published in Frontiers in Aging Neuroscience indicates that coenzyme maintenance is actively investigated in settings of altered turnover or inadequate synthesis. An innate physiological role does not prove that administering supplemental products produces clinical health improvements.

Human Pharmacokinetic Research and Blood Clearance Limits

Intravenously administered nicotinamide adenine dinucleotide clears from bloodstream circulation rapidly without producing an immediate increase in circulating plasma concentrations. A human pilot trial published by Grant and colleagues documented the plasma and urine metabolome in eight test participants and three control participants during a continuous six-hour intravenous infusion. The researchers observed that intact coenzyme was completely removed from the blood plasma for at least the initial two hours of administration.

Researchers measured NAD+ and its breakdown products in blood and urine. Blood levels did not change during the first two hours. At six hours, urine testing showed increased excretion of NAD+ and one breakdown product, while another showed no significant rise. (Source).

Documenting how human tissues clear an infused molecule does not establish clinical outcomes such as improved physical vigor, restored cognitive clarity, or extended lifespan. The investigators in the Grant pilot study evaluated metabolic clearance pathways rather than long-term clinical benefits. Furthermore, pharmacokinetic observations from continuous intravenous infusions do not demonstrate the clinical effects, absorption, or bioequivalence of subcutaneous or intramuscular store formulations.

Commercial Infusion Tolerability and Biomarker Observations

The cited commercial-clinic study reported different infusion symptoms and durations for intravenous NAD+ and nicotinamide riboside. A retrospective study published in PubMed (PMID 41704678) evaluated electronic medical records from a commercial clinic where participants received four consecutive daily infusions of either NAD+ or nicotinamide riboside (NR), followed by thirty days of observation. In this clinic sample, participants receiving the coenzyme experienced moderate to severe gastrointestinal symptoms, increased heart rate, and chest pressure during their sessions.

Individuals who received intravenous NR reported milder symptoms that included transient tongue, jaw, or arm tingling alongside mild cramping. The study reported an average infusion time of 97 minutes for the coenzyme group compared to 37 minutes for the precursor group. All reported infusion symptoms resolved upon completion of the infusion, and safety markers including liver enzymes, kidney indicators, and thyroid-stimulating hormone showed no significant alterations over thirty days, as reported in the commercial clinic tolerability study.

Exploratory biomarker evaluations revealed distinct metabolic shifts between the two groups over the thirty-day follow-up period. Participants in the coenzyme cohort showed a reduction in high-density lipoprotein cholesterol and a decrease in alkaline phosphatase, while the precursor cohort demonstrated a reduction in glycated hemoglobin. Neither group exhibited changes in fasting blood glucose or low-density lipoprotein cholesterol according to the PubMed comparative report.

These exploratory findings concern short-term observations in a commercial setting, but they do not establish anti-aging efficacy, disease prevention, or predictable outcomes for self-administered injections.

Findings From the Commercial Infusion Study

The following table reports the findings of the cited retrospective clinic study. (Source).

Evaluation Parameter	Intravenous NAD+ Group	Intravenous Nicotinamide Riboside Group
Average Infusion Time	97 minutes	37 minutes
Observed Infusion Symptoms	Moderate to severe gastrointestinal distress, increased heart rate, chest pressure	Mild tongue, jaw, or arm tingling, mild cramping
Reported Thirty-Day Metabolic Observations	Significant reduction in high-density lipoprotein cholesterol and alkaline phosphatase	Significant reduction in glycated hemoglobin (HbA1c)
Reported Laboratory Markers	No significant change in the measured liver and kidney markers	No significant change in the measured liver and kidney markers
Evidence Takeaway	Longer administration with higher symptom burden; requires physician oversight	Shorter infusion times with exploratory metabolic variations; requires further outcome trials

Sterile Compounding Standards and Regulatory Findings

Compounded injectable preparations present significant health risks if compounding facilities fail to use suitable pharmaceutical components. The FDA issued a public alert warning that some compounding pharmacies used food-grade raw materials to manufacture sterile injectable products. FDA warns that food-grade ingredients, without appropriate processing, are not suitable for sterile drugs because they may contain microbes and endotoxins.

Adverse event reports submitted to the FDA MedWatch reporting system describe individuals experiencing severe chills, shaking, vomiting, and fatigue following injections of compounded coenzyme preparations, with some patients requiring medical treatment. The agency noted that these acute physiological reactions are consistent with excessive levels of endotoxins.

According to official FDA compounding guidance, compounded medications do not undergo pre-market evaluation for safety, clinical effectiveness, or manufacturing consistency. This absence of agency review means that marketing assertions regarding cellular restoration or systemic rejuvenation have not been verified by regulatory authorities. Patients considering injectable therapies should evaluate them alongside licensed clinicians rather than ordering unverified products from internet sellers. (Source).

Delivery Routes and Alternative Precursor Considerations

The cited clinical studies do not establish that concentrated store injections achieve clinical outcomes superior to oral precursors or intravenous infusions. The cited studies do not establish superior cellular uptake for the store preparations. A treating physician must assess your individual medical context, tolerance, and biomarker status before selecting an administration route. (Source).

Direct human evidence for the exact store formulation and patient-relevant outcomes could change the evidence assessment. (Source).

The Opt Take on NAD+ Therapy

Determining whether injectable coenzyme support fits your personal health strategy begins with objective biomarker testing and individualized physician oversight. Every prospective member begins with an extensive blood panel evaluating 55+ biomarkers, covering sex hormones, metabolic indicators, systemic inflammation markers, and cardiovascular risk factors. (Source).

You review these diagnostic results during a dedicated 1:1 video consultation with an Opt Health physician on our HIPAA-compliant telemedicine platform. Prescriptions, peptides, and supplements can ship from our pharmacy to your home. Depending on your membership plan, follow-up blood panels and physician consultations occur two to four times per year, and our clinical care team remains reachable through in-app chat seven days a week. (Source).

To understand how our continuous diagnostic tracking functions, explore the step-by-step diagnostic sequence on our clinical evaluation process page.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop. (Source).

Frequently Asked Questions

What is the difference between NAD+ and NADH?

NAD+ represents the oxidized configuration of nicotinamide adenine dinucleotide, while NADH represents the reduced configuration carrying additional electrons. Cells continuously transfer electrons between these two states to drive mitochondrial respiration and generate cellular energy. (Source).

Are compounded NAD+ injections approved by the FDA?

Compounded medications, including injectable coenzyme formulations, are not approved by the FDA. According to official FDA compounding guidance, the regulatory agency does not verify the safety, clinical effectiveness, or manufacturing quality of compounded drugs prior to marketing.

What side effects were reported in clinical studies of intravenous NAD+?

In a retrospective study published in PubMed (PMID 41704678), participants receiving intravenous coenzyme infusions reported moderate to severe gastrointestinal distress, increased heart rate, and chest pressure during administration. These acute symptoms resolved once the infusion was completed.

Do intravenous studies prove the safety or efficacy of store injection vials?

The cited human intravenous trials, including the Grant metabolome study and the retrospective tolerability study, evaluated a human infusion pilot and a retrospective commercial-clinic sample. These studies do not establish the clinical outcomes, bioavailability, or safety profiles of subcutaneous or intramuscular store formulations.

How does an Opt Health physician determine if coenzyme support is appropriate?

An Opt Health physician evaluates your health history, existing medications, and baseline panel of 55+ biomarkers during a 1:1 consultation. (Source).

---

Review our structured telehealth membership plans to evaluate baseline biomarker testing options and physician-guided preventive care protocols. (Source).

References

1. Grant R, Berg J, Mestayer R, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Frontiers in Aging Neuroscience. 2019;11:257. Available from: PubMed PMID: 31572171.
2. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Available from: PubMed PMID: 41704678.
3. FDA. FDA reminds compounders to use ingredients suitable for sterile compounding. Published October 30, 2024. Available from: FDA Safety Alerts.
4. FDA. Compounding and the FDA: Questions and Answers. Available from: FDA Compounding Q&A.

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.